clinical trial · NCT05363449
Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis
Therapeutics, Inc.·phase1·completed·n = 42
Tinea CrurisTinea PedisUHE-103 CreamNaftin (naftifine hydrochloride) Cream
brief summary
This Phase 1 study has been designed to determine the safety, tolerability and pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use conditions for 2 weeks treatment in subjects with tinea cruris and/or tinea pedis
started
Feb 17, 2022
primary completion
Nov 14, 2023
completion
Nov 14, 2023
last updated
Apr 10, 2024
official title
An Open Label, Parallel Group Comparison Study To Evaluate the Safety Tolerability, and Pharmacokinetics of UHE-103 Cream Versus Naftin Cream in Subjects With Tinea Cruris and/or Tinea Pedis Under Maximal Use Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol